Brian Vickery, MD, discusses the mechanism, dose-escalation design, and outlook for a first-in-human microneedle immunotherapy trial for peanut allergy.
Brian P. Vickery, MD
Advertisement
Brian Vickery, MD, chief of allergy and immunology at Children's Healthcare of Atlanta.
Articles by Brian P. Vickery, MD
Investigators outline how phase 1 safety data could inform a phase 2 efficacy study and eventual pediatric enrollment down to age 4 years.
The first-in-human study is testing an ascending-dose microneedle device designed to deliver peanut protein through the skin in just 3 minutes.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH
2
EADV Congress 2026: Day 2 Recap—6 Headlines to Know
3
AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD
4
First-in-Class Oral ENV-294 Evaluated in Atopic Dermatitis, With Leon Kircik, MD
5